CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 350 enrolled
Drug / intervention
GW685698Xdrug
Likely dose
GW685698X 100 mcg nasal spray once dailyAI-extracted
Key inclusion· 3
  • ✓Outpatient status
  • ✓Confirmed diagnosis of vasomotor rhinitis
  • ✓Literate in English or native language
Key exclusion· 3
  • ✕Significant concomitant medical condition
  • ✕Concomitant corticosteroids or other allergy medications during the study
  • ✕Tobacco product use within the past year

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00118703
NCT00118703Phase 3Completed
CompareCT.gov

A 4 Week Randomized, Double Blind, Placebo Controlled Study of GW685698X Aq Nasal Spray 100mcg QD in Adults and Adolescents With Vasomotor Rhinitis

GlaxoSmithKline·interventional·Posted Jul 12, 2005·Updated Aug 21, 2017

In Brief

A Phase 3 clinical trial evaluating GW685698X for Vasomotor Rhinitis and Rhinitis, Vasomotor. Completed, enrolled 350 participants across 59 sites in 7 countries.

Detailed Summary

The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 years of age and older) with vasomotor rhinitis (VMR).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVasomotor Rhinitis, Rhinitis, Vasomotor
CountriesCanada, Czechia, Germany, Norway, Puerto Rico, Romania, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 12, 2005
Enrollment StartJul 1, 2005
Primary CompletionFeb 1, 2006
Study CompletionFeb 9, 2006
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 21.0 years ago

Interventions

GW685698Xdrug